JPMorgan Upgrades Biogen Ahead of Key Data Readouts
JPMorgan analysts say Biogen is on an increasingly promising path, citing several key data readouts expected next year, including for felzartamab.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
American Express, Biogen upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express (AXP) to Overweight from Neutral with a price target of $400, up from $328. The company trades at a